Ameritas Advisory Services LLC Buys 90,384 Shares of Pfizer Inc. $PFE

Key Points

• Ameritas Advisory Services LLC increased its Pfizer stake by 241.1% in the fourth quarter, buying 90,384 additional shares and bringing its total holding to 127,869 shares worth about $3.18 million.
• Pfizer reported better-than-expected quarterly results, posting EPS of $0.75 versus the $0.72 consensus and revenue of $14.45 billion, up 5.4% from a year earlier.
• The company also announced a quarterly dividend of $0.43 per share, equal to a 6.6% annualized yield, while analysts currently rate the stock a consensus Hold with an average price target of $28.74.

Ameritas Advisory Services LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 241.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 127,869 shares of the biopharmaceutical company's stock after buying an additional 90,384 shares during the quarter. Ameritas Advisory Services LLC's holdings in Pfizer were worth $3,184,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Pfizer by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. State Street Corp raised its stake in Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company's stock valued at $7,620,747,000 after purchasing an additional 2,786,098 shares in the last quarter. Northern Trust Corp lifted its position in Pfizer by 1.4% during the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company's stock valued at $1,631,225,000 after purchasing an additional 869,175 shares during the last quarter. Fisher Asset Management LLC grew its stake in Pfizer by 1.9% in the 3rd quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company's stock worth $1,255,860,000 after buying an additional 897,786 shares in the last quarter. Finally, Legal & General Group Plc grew its stake in Pfizer by 8.6% in the 3rd quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company's stock worth $1,063,565,000 after buying an additional 3,296,415 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.3%

NYSE PFE opened at $25.96 on Thursday. The firm has a market cap of $147.93 billion, a PE ratio of 19.81 and a beta of 0.35. Pfizer Inc. has a 1-year low of $21.97 and a 1-year high of $28.75. The stock has a 50-day moving average of $27.03 and a 200-day moving average of $26.19. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period last year, the company earned $0.92 EPS. Pfizer's revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer's dividend payout ratio (DPR) is presently 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won European Commission approval to expand HYMPAVZI (marstacimab) for hemophilia A and B patients with inhibitors, a label expansion that could help broaden future sales. European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
• Positive Sentiment: Analyst coverage highlighted Pfizer’s rebound story, with the company targeting high-single-digit revenue CAGR from 2029 as new launches, acquisitions, and pipeline growth may offset patent-expiration headwinds. Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029?
• Positive Sentiment: Multiple market commentators argued Pfizer looks undervalued after recent earnings, with some calling it a possible long-term buying opportunity and noting healthy underlying results despite a muted reaction. Top Analyst Reports for Meta, Pfizer & Salesforce
• Neutral Sentiment: Pfizer and partner Arvinas licensed VEPPANU (vepdegestrant) rights to Rigel Pharmaceuticals, bringing Pfizer $85 million in upfront and transition payments plus potential milestones and royalties, but also ceding commercialization control. Pfizer Shifts VEPPANU Rights To Rigel As Valuation Gap Persists
• Negative Sentiment: Bearish commentary continued to focus on Pfizer’s post-pandemic slowdown, with articles questioning dividend sustainability and whether the company can regain stronger growth as older products face loss of exclusivity. Pfizer's Net Income Drops in Q1. Is Its Dividend Still Safe?
• Negative Sentiment: Broader sector coverage also pointed to tougher vaccine demand conditions in the U.S., which could weigh on sentiment toward large pharma names including Pfizer. How tough is it getting for vaccine makers in the U.S.?

Analyst Ratings Changes

PFE has been the topic of several research reports. Cantor Fitzgerald restated a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday, May 9th. Bank of America lowered their price target on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Thursday, April 9th. Argus upgraded Pfizer from a "hold" rating to a "buy" rating and set a $35.00 price objective for the company in a report on Monday, March 2nd. Finally, CICC Research initiated coverage on Pfizer in a research report on Thursday, April 16th. They set an "outperform" rating and a $33.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and an average price target of $28.74.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.